Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study
Real-world evidence from China shows how long patients should take imatinib before surgery for rare stomach tumors, guiding treatment planning where trial data is scarce.
A nationwide retrospective study from China examined how the duration of perioperative imatinib targeted therapy affects survival in GIST patients undergoing neoadjuvant treatment before surgery. The findings provide real-world evidence on optimal imatinib duration with practical implications for GIST management guidelines, particularly where duration decisions lack strong prospective trial evidence.
What the study was
- Study design
- Nationwide retrospective cohort study of perioperative imatinib duration in GIST (China)
- Population
- GIST patients undergoing neoadjuvant imatinib in China (nationwide registry)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Eur J Surg Oncol
Why it surfaced
Nationwide retrospective evidence on neoadjuvant imatinib duration in GIST; practice-guiding real-world data with direct clinical translation for targeted therapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.